Condition (MeSH)
Giant Cell Tumor of Bone
ClinicalTrials.gov lists 22 trials for Giant Cell Tumor of Bone or a narrower condition beneath it. Amgen has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Giant Cell Tumor of Bone itself; the rest are tagged with a narrower condition beneath it.
When did Giant Cell Tumor of Bone trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Giant Cell Tumor of Bone trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Observational | 7 |
How many Giant Cell Tumor of Bone trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 2 |
| Completed | 8 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Giant Cell Tumor of Bone trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Amgen | 4 |
| Shanghai JMT-Bio Inc. | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
Which drugs are being tested for Giant Cell Tumor of Bone? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DENOSUMAB | 8 |
| NIVOLUMAB | 1 |
| IPILIMUMAB | 1 |
| Cytoxan | 1 |
| Narlumosbart | 1 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| acid Zoledronic | 2 |
| Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | 1 |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | 1 |
| ICG | 1 |
| Indocyanine Green dye | 1 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Giant Cell Tumor of Bone trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 34 | 1 |
| Pleural effusion | 30 | 1 |
| Osteonecrosis of jaw | 26 | 2 |
| Nausea | 22 | 3 |
| Bone giant cell tumour | 19 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Giant Cell Tumor of Bone? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison. | Cancer medicine | 2025 | Yes |
| Narlumosbart: First Approval. | Drugs | 2024 | Yes |
| Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study. | Nature communications | 2024 | Yes |
| Giant cell tumour of bone. | The bone & joint journal | 2023 | Yes |
| Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study. | The oncologist | 2023 | Yes |
Showing 5 of 34 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Giant cell tumor of bone | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Giant cell tumor of bone | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Giant cell tumor of bone | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Giant cell tumor of bone | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Giant cell tumor of bone | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Giant cell tumor of bone | 363976 | Exact | Orphadata Science knowledge files, Product 1 |
| Giant cell tumor of bone | 363976 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.